comparemela.com

Latest Breaking News On - Advisors lp baker - Page 11 : comparemela.com

Bros. Advisors Lp Baker Buys 1,888,800 Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Stock

Bros. Advisors Lp Baker Buys 1,888,800 Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Us-bancorp
Nasdaq
Neoleukin-therapeutics-inc
Walleye-capital
Hightower-advisors
Neoleukin-therapeutics
Get-free-report
Advisors-lp-baker
Tower-advisors
Jane-street-group
Neoleukin-therapeutics-daily

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Director Bros. Advisors Lp Baker Purchases 166,942 Shares

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) Director Bros. Advisors Lp Baker purchased 166,942 shares of the stock in a transaction on Thursday, August 17th. The stock was acquired at an average cost of $0.69 per share, for a total transaction of $115,189.98. Following the completion of the acquisition, the director now owns 5,612,949 […]

Securities-exchange-commission
Neoleukin-therapeutics-inc
Kestra-private-wealth-services
Shay-capital
Walleye-capital
Nasdaq
Virtu-financial
Neoleukin-therapeutics
Get-free-report
Advisors-lp-baker
Exchange-commission

ACADIA Pharmaceuticals (NASDAQ:ACAD) Rating Reiterated by Oppenheimer

Oppenheimer reissued their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report report published on Thursday, Benzinga reports. They currently have a $25.00 price target on the biopharmaceutical company’s stock. Other analysts have also recently issued research reports about the stock. JMP Securities upped their price objective on […]

United-states
China
America
James-kihara
Pharmaceuticals-trading-down
Cm-bidwell-associates-ltd
Securities-exchange-commission
Pharmaceuticals-daily
Jpmorgan-chase-co
Nasdaq
China-universal-asset-management-co
Pharmaceuticals-company-profile

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $38.00 by Analysts at Canaccord Genuity Group

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price lowered by Canaccord Genuity Group from $39.00 to $38.00 in a research report released on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Other equities research analysts also recently issued reports about the company. StockNews.com began coverage […]

China
United-states
America
Stephen-davis
Pharmaceuticals-stock-down
Acadia-pharmaceuticals
Nemes-rush-group
Morgan-stanley
Canaccord-genuity-group
Pharmaceuticals-company-profile
Cm-bidwell-associates-ltd
Nisa-investment-advisors

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $23.00 Price Target at Oppenheimer

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $23.00 Price Target at Oppenheimer
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

China
United-states
America
Stephen-davis
Cm-bidwell-associates-ltd
Citigroup
Exchange-traded-concepts
Acadia-pharmaceuticals
Credit-suisse-group
Nisa-investment-advisors
Pharmaceuticals-stock-performance
Pharmaceuticals-daily
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.